...
首页> 外文期刊>Clinical Chemistry: Journal of the American Association for Clinical Chemists >Real-Time Quantitative Reverse Transcription-PCR for Cyclin D1 mRNA in Blood, Marrow, and Tissue Specimens for Diagnosis of Mantle Cell Lymphoma
【24h】

Real-Time Quantitative Reverse Transcription-PCR for Cyclin D1 mRNA in Blood, Marrow, and Tissue Specimens for Diagnosis of Mantle Cell Lymphoma

机译:实时定量逆转录PCR技术检测血液,骨髓和组织标本中的Cyclin D1 mRNA,以诊断套细胞淋巴瘤

获取原文
           

摘要

Background: Overexpression of cyclin D1 mRNA, found in mantle cell lymphoma (MCL), is a critical diagnostic marker. We investigated the use of real-time reverse transcription-PCR (RT-PCR) for cyclin D1.Methods: We studied 97 fresh specimens (50 blood, 30 bone marrow, 15 lymph node, and 2 other samples) from patients diagnosed with a variety of lymphoproliferative diseases, including 25 cases of MCL. We used real-time quantitative RT-PCR to evaluate cyclin D1 mRNA expression. Because blood and marrow specimens may contain only a minority of potentially malignant cells (as opposed to most lymph nodes) and to increase sensitivity, we normalized the cyclin D1 mRNA concentrations to mRNA of a B-cell-specific marker, CD19, as well as to previously characterized β2-microglobulin mRNA.Results: In 16 of 21 cases of MCL with overt disease, the ratio of cyclin D1 mRNA to β2-microglobulin mRNA was increased, but all 21 cases showed increased ratios of cyclin D1 mRNA to CD19 mRNA. Cyclin D1 mRNA was low or undetectable in various lymphoproliferative diseases, including cases of ambiguous immunophenotype. The mRNA ratios were stable over 3–7 days of sample storage.Conclusion: Quantitative RT-PCR for cyclin D1 mRNA normalized to CD19 mRNA can be used in the diagnosis of MCL in blood, marrow, and tissue.
机译:背景:在套细胞淋巴瘤(MCL)中发现的细胞周期蛋白D1 mRNA过表达是关键的诊断标记。我们研究了实时反转录PCR(RT-PCR)对细胞周期蛋白D1的使用方法:我们研究了97例新鲜标本(50血,30骨髓,15淋巴结和2个其他样本)多种淋巴增生性疾病,包括25例MCL。我们使用实时定量RT-PCR来评估细胞周期蛋白D1 mRNA表达。由于血液和骨髓标本可能仅包含少数潜在的恶性细胞(与大多数淋巴结相反),并且为了提高敏感性,因此我们将细胞周期蛋白D1 mRNA浓度标准化为B细胞特异性标记物CD19和结果:在21例明显疾病的MCL中,有16例细胞周期蛋白D1 mRNA与β2-微球蛋白mRNA的比率增加,但所有21例中细胞周期蛋白D1 mRNA与CD19 mRNA的比率均增加。在多种淋巴细胞增生性疾病(包括免疫表型不明确的病例)中,细胞周期蛋白D1 mRNA的表达水平较低或无法检测到。在保存样品的3–7天中,mRNA比率保持稳定。结论:定量RT-PCR可以将CD19 mRNA标准化的细胞周期蛋白D1 mRNA定量用于血液,骨髓和组织中的MCL诊断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号